Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bluebird bio, Inc.

< Previous 1 2 3 Next >
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE CG
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE CG
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE CG
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE CG
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE CG
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces 1-for-20 Reverse Stock Split
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Receipt of Expected Notices from Nasdaq
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Second Quarter 2024 Results Call Date
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Appoints O. James Sterling as Chief Financial Officer
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.